Skip to Content

Fingolimod Dosage

Medically reviewed on August 28, 2017.

Applies to the following strengths: 0.5 mg

Usual Adult Dose for Multiple Sclerosis

0.5 mg orally once daily

Comments: Monitor with first dose (see WARNINGS section).

Use: For the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Closely monitor patients.


The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for fingolimod. It includes a communication plan. For additional information:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Take with or without food.
-Doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit.

Storage requirements: Store at room temperature in the original blister pack; protect from moisture.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.